Navigation Links
Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013

PHILADELPHIA and REHOVOT, Israel, April 2, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that two posters related to the Company's microRNA-based diagnostic assays will be featured at the American Association for Cancer Research (AACR) Annual Meeting 2013, to be held April 6-10 at the Walter E. Washington Convention Center in Washington, D.C.  Both posters will be presented by Mats Sanden , M.D., Medical & Laboratory Director, Rosetta Genomics and will be available for viewing Sunday, April 7 from 1:00-5:00 p.m. local time in the Molecular and Cellular Biology 12 Session in Hall A-C, Poster Section 34.  The two posters are as follows:

Title: "Development and validation of a microRNA-based diagnostic assay for the classification of renal cell tumors"
Abstract number: 802
Summary: This poster describes the development and validation of the miRview® kidney assay, which differentiates between the four main types of primary kidney tumors. The assay was developed on a microarray platform using 181 training samples and validated blindly on an independent set of 201 samples. The assay was able to return results for 92% of the validation samples, with 95% accuracy.

Title: "A novel microRNA-based test demonstrates 92% accuracy in the classification of metastatic tumors from patients diagnosed with carcinoma of unknown primary"
Abstract number: 816
Summary: This study reports the performance and clinical utility of miRview® mets2, a microRNA-based molecular diagnostic assay for identifying the tissue of origin in real cases of cancer of unknown or uncertain primary (CUP) patients collected by leading academic centers in Greece.  The assay demonstrated agreement in 92% of the cases with all pathological and clinical information, including patient follow-up data. Results of this study demonstrate the assay to be a helpful tool for identifying the correct final clinical diagnosis and in facilitating the selection of optimal therapy, including targeted agents, early in the disease course.

"Attendees at the prestigious AACR annual meeting are an important audience for Rosetta Genomics, and we are delighted that studies involving our microRNA-based diagnostic assays in kidney cancer and cancer of unknown or uncertain primary are being featured this year," said Kenneth A. Berlin , President and Chief Executive Officer of Rosetta Genomics.

"The classification of tumors into subtypes of renal cell cancer (RCC) has historically been less than definitive by histology, cytology and immunohistochemistry, particularly in the growing context of smaller, non-resection derived diagnostic specimens.  Expanded clarity of RCC diagnosis through the availability of the miRview® kidney assay will help lead to improved rationalization and optimization of therapies both new and emerging," said Bob Wassman , M.D., Chief Medical Officer of Rosetta Genomics.

Regarding the second poster on CUP diagnosis by Rosetta's proprietary microRNA-based miRview® mets2 assay, he added, "Where clinical and immunohistochemical data are available, but uncertain, the resulting molecular diagnoses from our assay will generally fall within the range of possible cancers but more precisely and with no subjectivity, and will, with much higher confidence, identify one tumor type. There are also hallmark cases where unusual tumors of origin have actually been found only after molecular analysis, both of which are critical advances for these patients."

About miRview® Testing Services

miRview® assays are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. miRview® mets² accurately identifies the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). miRview® meso diagnoses mesothelioma, a cancer connected to asbestos exposure.  miRview® lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. miRview® kidney accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.  miRview® assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment.  In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview® mets² assay, 60,000 from miRview® meso, 65,000 from miRview® kidney and 226,000 patients from miRview® lung. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's miRview® testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.  Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to Rosetta's  development or commercialization of molecular diagnostics, the market acceptance of Rosetta's miRview® assays, particularly miRview® mets2, Rosetta's capitalization of its microRNA platform, Rosetta's patent position and Rosetta's development of personalized medicine products and services constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact:     
Rosetta Genomics         
Ken Berlin , President & CEO                      
(215) 382-9000, ext. 326             

Investor Contacts:             
Anne Marie Fields
(212) 838-3777
Bruce Voss
(310) 691-7100

SOURCE Rosetta Genomics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
2. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
3. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
4. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
5. Squished bug genomics: Insect goo aids biodiversity research
6. BGI-Shenzhen Completes Acquisition of Complete Genomics
7. Genomics Data Management Leader Annai Systems Offers Shortcut to Analysis
8. Real Time Genomics Announces Formation of its Scientific Advisory Board
9. Real Time Genomics® Announces Platform Launch, Expanding Commercial Operations
10. TopCoders Open Community Challenge Process Yields 970 Fold Increase in Speed for Big Data Genomics Sequencing Algorithm
11. Boston Childrens Hospital announces international genomics competition winner
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and ... they have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas ... tools for gene editing across all applications. , Under the terms of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
Breaking Biology Technology:
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):